USAN Council's Statement on the Use of USAN as Domain Names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
The following names for the drugs described are "under consideration" by the USAN Council:
aflibercept
angiogenesis inhibitor
bardoxolone methyl
antineoplastic agent, anticarcinogenesis agent, cancer supportive agent, immunomodulatory, and/or anti-inflammatory agent
bexalomer
treatment of hyperphosphatemia
coleneuramide
prevention of progression in patients with diabetic neuropathy
denenicokin
treatment of cancer
efungumab
treating infections of C. Albicans
farletuzumab
treatment of cancer
fidaxomicin
antibacterial
fosbretabulin disodium
treatment of cancer and ophthalmic diseases
fostamatinib disodium
treatment of rheumatoid arthritis
gantenerumab
treatment of Alzheimer's disease
hydroxyethyl starch 130/0.4
prophylaxis of hypervolemia
ifegostat
treatment of Gaucher's disease
ilimapimod
treatment of atherosclerosis, neuropathic pain and chronic obstructive pulmonary disease
ingenol mebutate
topical treatment of actinic keratosis
ixutumumab
treatment of solid tumors
lomtapide
treatment of vitamin B folic acid deficiency
losmapimod
treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, major depressive disorder, atherosclerosis
nelotanserin
treatment of sleep disorders
pozanicline
attention-deficit hyperactivity disorder, Alzheimer's-type dementia
ramucirumab
treatment of solid tumors
rezatomidine
treatment of neuropathic pain
rintalizumab
treatment of systemic lupus erythematosus
robatumumab
treatment of cancer (inhibits insulin-like growth factor 1 receptor, IGF-1R)
saplintide
treatment of obesity and obesity-related disorders, such as diabetes
sofinicline
attention-deficit hyperactivity disorder, Alzheimer's-type dementia, diabetic neuropathy
sonedenoson
wound healing, adenosine A2a receptor agonist
spinosad
pediculicide (human health), ecto parasiticide (animal health)
stolanezumab
treatment of Alzheimer's disease
tafamabril
treatment of transthyretin-associated amyloidosis
terofexro isopropyl
treatment of lipid disorders
tozasertib lactate
treatment of cancer
tylvalosin
veterinary antibiotic
varlitinib
antineoplastic
vatactant
lung surfactant replacement
vedolizumab
ulcerative colitis and Crohn's disease
Any comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 515 North State Street, Chicago, IL 60654, or sent via e-mail to USAN@ama-assn.org.
Content provided by: USAN